Albash Buthainah, Imtiaz Faiqa, Al-Zaidan Hamad, Al-Manea Hadeel, Banemai Mohammed, Allam R, Al-Suheel Ali, Al-Owain Mohammed
Medical Genetics Centre, Kuwait City, Kuwait.
Eur J Pediatr. 2014 May;173(5):647-53. doi: 10.1007/s00431-013-2223-0. Epub 2013 Dec 11.
Glycogen storage disease type IX (GSD IX) is a common form of glycogenosis due to mutations in PHKA1, PHKA2, or PHKB and PHKG2 genes resulting in the deficiency of phosphorylase kinase. The first two genes are X-linked while the latter two follow an autosomal recessive inheritance. The majority of cases of GSD IX are attributed to defects in PHKA2 which usually cause a mild disease. We report three patients with PHKG2-related GSD IX presenting with significant hepatic involvement, fibrosis, and cirrhosis. Interestingly, the homozygosity mapping resolved a dilemma about an erroneously normal phosphorylase kinase activity in patient 1. The novel mutation found in all the three patients (p.G220E) affects the catalytic subunit of the phosphorylase kinase. Increasing evidence shows that patients with PHKG2 mutations have a severe hepatic phenotype within the heterogeneous GSD IX disorder. Therefore, defect in PHKG2 should be considered in patients with suspected glycogenosis associated with significant liver fibrosis and cirrhosis.
IX型糖原贮积病(GSD IX)是糖原贮积症的一种常见形式,由于PHKA1、PHKA2、PHKB或PHKG2基因突变导致磷酸化酶激酶缺乏。前两个基因是X连锁的,而后两个基因遵循常染色体隐性遗传。大多数GSD IX病例归因于PHKA2缺陷,通常导致轻度疾病。我们报告了3例与PHKG2相关的GSD IX患者,表现为严重的肝脏受累、纤维化和肝硬化。有趣的是,纯合子定位解决了患者1中磷酸化酶激酶活性错误正常的困境。在所有3例患者中发现的新突变(p.G220E)影响磷酸化酶激酶的催化亚基。越来越多的证据表明,在异质性GSD IX疾病中,PHKG2突变患者具有严重的肝脏表型。因此,对于疑似糖原贮积症且伴有明显肝纤维化和肝硬化的患者,应考虑PHKG2缺陷。